Clinical Trial: NCT02435849
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2024-02-13 |
Study Overview
Brief Summary
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
Official Title
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia
Intervention / Treatment
- Biological: CTL019
Other Study ID Numbers
- CCTL019B2202
- 2013-003205-25
Start Date (Actual)
2015-04-08
Primary Completion Date (Actual)
2020-01-21
Study Completion Date (Actual)
2022-11-17
Enrollment (Actual)
80
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2024-02-13 |
Study Overview
Brief Summary
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
Official Title
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia
Intervention / Treatment
- Biological: CTL019
Other Study ID Numbers
- CCTL019B2202
- 2013-003205-25
Start Date (Actual)
2015-04-08
Primary Completion Date (Actual)
2020-01-21
Study Completion Date (Actual)
2022-11-17
Enrollment (Actual)
80
Study Type
Interventional
Phase
Phase 2